Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Correlation of spot urinary protein: Creatinine ratio and quantitative proteinuria in pediatric patients with nephrotic syndrome.

Singh R, Bhalla K, Nanda S, Gupta A, Mehra S.

J Family Med Prim Care. 2019 Jul;8(7):2343-2346. doi: 10.4103/jfmpc.jfmpc_403_19.

2.

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD.

Am J Hematol. 2019 Aug 10. doi: 10.1002/ajh.25610. [Epub ahead of print] No abstract available.

PMID:
31400013
3.

Inhibition of phosphoenolpyruvate carboxykinase blocks lactate utilization and impairs tumor growth in colorectal cancer.

Montal ED, Bhalla K, Dewi RE, Ruiz CF, Haley JA, Ropell AE, Gordon C, Haley JD, Girnun GD.

Cancer Metab. 2019 Aug 1;7:8. doi: 10.1186/s40170-019-0199-6. eCollection 2019.

4.

Pattern and determinants of soil-transmitted helminthiasis in a rural area of Haryana: A school-based study.

Dhaka R, Verma R, Kumar R, Chayal V, Bhalla K, Singh R, Agrawal G, Kumar G.

J Family Med Prim Care. 2019 Jun;8(6):1971-1975. doi: 10.4103/jfmpc.jfmpc_278_19.

5.

Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)-induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells.

Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K.

Clin Cancer Res. 2019 Jul 1;25(13):4195. doi: 10.1158/1078-0432.CCR-19-1602. No abstract available.

PMID:
31263034
6.

Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD.

Am J Surg Pathol. 2019 Oct;43(10):1429-1437. doi: 10.1097/PAS.0000000000001316.

PMID:
31261288
7.

Going to the nearest hospital vs. designated trauma centre for road traffic crashes: estimating the time difference in Delhi, India.

Ahuja R, Tiwari G, Bhalla K.

Int J Inj Contr Saf Promot. 2019 Sep;26(3):271-282. doi: 10.1080/17457300.2019.1626443. Epub 2019 Jun 26.

PMID:
31240990
8.

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaav5599. doi: 10.1126/scitranslmed.aav5599.

9.

Practices and knowledge regarding dengue infection among the rural community of Haryana.

Verma R, Bhalla K, Dhankar M, Kumar R, Dhaka R, Agrawal G.

J Family Med Prim Care. 2019 May;8(5):1752-1754. doi: 10.4103/jfmpc.jfmpc_6_19.

10.

Epidemiology and clinical outcomes of acute glomerulonephritis in a teaching hospital in North India.

Bhalla K, Gupta A, Nanda S, Mehra S.

J Family Med Prim Care. 2019 Mar;8(3):934-937. doi: 10.4103/jfmpc.jfmpc_57_19.

11.

Beneficial effects of gluten free diet on IgA tissue transglutaminase levels and various growth parameters in celiac disease patients.

Hota D, Bhalla K, Nanda S, Gupta A, Mehra S.

J Family Med Prim Care. 2019 Mar;8(3):823-827. doi: 10.4103/jfmpc.jfmpc_56_19.

12.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
13.

Building Road Safety Institutions in Low- and Middle-Income Countries: The Case of Argentina.

Bhalla K, Shotten M.

Health Syst Reform. 2019;5(2):121-133. doi: 10.1080/23288604.2019.1565061. Epub 2019 Mar 8.

PMID:
30848990
14.

Using street imagery and crowdsourcing internet marketplaces to measure motorcycle helmet use in Bangkok, Thailand.

Merali HS, Lin LY, Li Q, Bhalla K.

Inj Prev. 2019 Mar 4. pii: injuryprev-2018-043061. doi: 10.1136/injuryprev-2018-043061. [Epub ahead of print]

PMID:
30833286
15.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN.

Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.

16.

Community perception about swine flu in an urban slum of Haryana: A cross-sectional study.

Verma R, Chayal V, Kumar R, Bhalla K, Dhankar M, Dhaka R, Agrawal G.

J Family Med Prim Care. 2018 Nov-Dec;7(6):1515-1520. doi: 10.4103/jfmpc.jfmpc_151_18.

17.

Prevalence of bronchial asthma and its associated risk factors in school-going adolescents in Tier-III North Indian City.

Bhalla K, Nehra D, Nanda S, Verma R, Gupta A, Mehra S.

J Family Med Prim Care. 2018 Nov-Dec;7(6):1452-1457. doi: 10.4103/jfmpc.jfmpc_117_18.

18.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.

PMID:
30575820
19.

An Approach Towards Reducing Road Traffic Injuries and Improving Public Health Through Big Data Telematics: A Randomised Controlled Trial Protocol.

Azmin M, Jafari A, Rezaei N, Bhalla K, Bose D, Shahraz S, Dehghani M, Niloofar P, Fatholahi S, Hedayati J, Jamshidi H, Farzadfar F.

Arch Iran Med. 2018 Nov 1;21(11):495-501.

20.

Improving quality of care during childbirth in primary health centres: a stepped-wedge cluster-randomised trial in India.

Agarwal R, Chawla D, Sharma M, Nagaranjan S, Dalpath SK, Gupta R, Kumar S, Chaudhuri S, Mohanty P, Sankar MJ, Agarwal K, Rani S, Thukral A, Jain S, Yadav CP, Gathwala G, Kumar P, Sarin J, Sreenivas V, Aggarwal KC, Kumar Y, Kharya P, Bisht SS, Shridhar G, Arora R, Joshi K, Bhalla K, Soni A, Singh S, Devakirubai P, Samuel R, Yadav R, Bahl R, Kumar V, Paul VK; QI Haryana Study Collaboration .

BMJ Glob Health. 2018 Oct 8;3(5):e000907. doi: 10.1136/bmjgh-2018-000907. eCollection 2018.

21.

Fulminant subacute sclerosing panencephalitis in an immunized 20-month-old Indian boy.

Khursheed A, Hota D, Bhalla K, Kaushik JS.

Neurosciences (Riyadh). 2018 Oct;23(4):351-353. doi: 10.17712/nsj.2018.4.20180168. No abstract available.

PMID:
30351295
22.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15.

PMID:
30328139
23.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

24.

De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD.

FASEB J. 2018 Jun 15:fj201800204. doi: 10.1096/fj.201800204. [Epub ahead of print]

PMID:
29906244
25.

Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes.

DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G.

J Immunol. 2018 Jul 1;201(1):124-133. doi: 10.4049/jimmunol.1800101. Epub 2018 May 11.

26.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2019 Jan;60(1):37-48. doi: 10.1080/10428194.2018.1464158. Epub 2018 May 9.

PMID:
29741984
27.

Author Correction: Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 May 3;8(1):7221. doi: 10.1038/s41598-018-25251-9.

28.

Estimating city-level travel patterns using street imagery: A case study of using Google Street View in Britain.

Goel R, Garcia LMT, Goodman A, Johnson R, Aldred R, Murugesan M, Brage S, Bhalla K, Woodcock J.

PLoS One. 2018 May 2;13(5):e0196521. doi: 10.1371/journal.pone.0196521. eCollection 2018.

29.

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.

Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, Evens AM, Gartenhaus RB.

Nat Commun. 2018 Feb 26;9(1):829. doi: 10.1038/s41467-018-03028-y.

30.

Unilateral Transient Watershed Cerebral Infarct in a 6-Year-Old Girl with Frequently Relapsing Nephrotic Syndrome.

Bhalla K, Garg D, Rajan M, Kaushik JS, Gathwala G.

J Nat Sci Biol Med. 2018 Jan-Jun;9(1):90-92. doi: 10.4103/jnsbm.JNSBM_133_17.

31.

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 Jan 15;8(1):744. doi: 10.1038/s41598-018-19182-8. Erratum in: Sci Rep. 2018 May 3;8(1):7221.

32.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

33.

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M.

Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.

34.

Targeting cistrome and dysregulated transcriptome of post-MPN sAML.

Verstovsek S, Fiskus W, Manshouri T, Bhalla KN.

Oncotarget. 2017 Oct 11;8(55):93301-93302. doi: 10.18632/oncotarget.21752. eCollection 2017 Nov 7. No abstract available.

35.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.

Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD.

Int J Mol Sci. 2017 Jul 26;18(8). pii: E1618. doi: 10.3390/ijms18081618.

36.

Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer.

Benton CB, Fiskus W, Bhalla KN.

Cancer J. 2017 Sep/Oct;23(5):286-291. doi: 10.1097/PPO.0000000000000284. Review.

PMID:
28926429
37.

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.

Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN.

Leukemia. 2018 Feb;32(2):343-352. doi: 10.1038/leu.2017.207. Epub 2017 Jun 30.

PMID:
28663582
38.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.

39.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S.

Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.

40.

Impact of improving vehicle front design on the burden of pedestrian injuries in Germany, the United States, and India.

Moran D, Bose D, Bhalla K.

Traffic Inj Prev. 2017 Nov 17;18(8):832-838. doi: 10.1080/15389588.2017.1324200. Epub 2017 May 1.

PMID:
28459283
41.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.

Cancer. 2017 Aug 15;123(16):3050-3060. doi: 10.1002/cncr.30704. Epub 2017 Apr 7.

42.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2017 Jul;31(7):1658. doi: 10.1038/leu.2017.77. Epub 2017 Mar 21.

PMID:
28322226
43.

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2.

44.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

45.

Giant Primary Epithelial Splenic Cyst in an Adolescent Girl.

Kajal P, Rattan KN, Bhutani N, Bhalla K.

APSP J Case Rep. 2016 Nov 1;7(5):42. eCollection 2016 Nov-Dec. No abstract available.

46.

Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src.

Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22841. No abstract available.

47.

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN.

Leukemia. 2017 Mar;31(3):678-687. doi: 10.1038/leu.2016.260. Epub 2016 Sep 28.

48.

Estimating the burden of injury in urban and rural Sudan in 2008.

Abdalla S, Ahmed S, Swareldahab Z, Bhalla K; Sudan Burden of Injury Team.

Inj Prev. 2017 Jun;23(3):171-178. doi: 10.1136/injuryprev-2016-042067. Epub 2016 Oct 11.

PMID:
27729441
49.

Asplenia Syndrome in a Neonate: A Case Report.

Bhalla K, Singh J, Yadav J, Mehra S.

J Clin Diagn Res. 2016 Jun;10(6):SD05-6. doi: 10.7860/JCDR/2016/18535.8028. Epub 2016 Jun 1.

50.

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.

Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN.

Cancer Res. 2016 Sep 15;76(18):5467-78. doi: 10.1158/0008-5472.CAN-16-0126. Epub 2016 Aug 8.

Supplemental Content

Loading ...
Support Center